Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Still In The Race: Achillion Says Its HCV Candidates Are “Best-In-Class”

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

In a year of turmoil in HCV drug development, Achillion has advanced just by staying steady. The biotech’s plans are rooted in an NS5A inhibitor that shows efficacy in patients with mutated strains of the virus and a strong-performing protease inhibitor.

You may also be interested in...



High-Premium Buyouts Continue In Hepatitis C Space; Are Idenix And Achillion Next?

Bristol’s $2.5 billion tender for Inhibitex left many industry observers waiting to see what HCV players will do with only two independent pure-play HCV biotechs left. Idenix is eager to get its mid-stage nucleotide free of an FDA partial clinical hold, while Achillion says it has the assets to go it alone in the HCV competition.

US FDA Appears To Quickly Renege On Next-Gen COVID Vaccine Guidance With Updated Booster Announcement

After issuing guidance and making public statements saying the first updated COVID-19 vaccines would require clinical trial data, agency picks new vaccine composition that will make obtaining such data highly unlikely before a planned fall booster campaign. 

EU Sustainable Chemicals Program Could Impact 60% Of Fragrance Ingredients – Givaudan

Certain rose, jasmine, cedarwood, freesia, lavender, apple, orange and musk fragrance ingredients could be eliminated purely on the basis of hazard if EU sustainable chemical principles are implemented as discussed across sectors and regulatory programs, according to Givaudan’s Greg Adamson, senior VP, global regulatory affairs and product safety for fragrance and beauty.

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

PS004968

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel